peptidylprolyl isomerase A pseudogene 52Genealiases: []
Q-omics provides the consensus-scored PPIAP52 profile across patient tissues and cancer cell-line models. PPIAP52 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PPIAP52 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PPIAP52 RNA expression shows 13,479 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, HNSC, and GBM as cancer lineages where PPIAP52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP52 survival associations across molecular data types. PPIAP52 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP52 RNA expression–survival associations across cancer types. High PPIAP52 expression shows unfavorable associations in STAD, KIRC, LUAD and PCPG, but favorable associations in ESCA and BRCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for PPIAP52 RNA expression.
This table summarizes PPIAP52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP52 shows lower tumor expression in KIRC and higher tumor expression in HNSC, THCA, BLCA, UCEC and CHOL. The HNSC box plot shows higher PPIAP52 RNA expression in tumor versus normal tissue (log2 FC = +0.182, t-test p < 0.001).
This table shows molecular features associated with PPIAP52 in patient tissues and cancer cell lines. In patient samples, PPIAP52 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
